Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher

Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.

ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer

Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy

Biocon Sdn. Bhd. enters Malaysia Book of Records

The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR

Valiant Organics to start production of OAP and Pharma Intermediates

Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23

Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery

The WAVEsystem with the WAVEcontrol 4.0 embedded

Sandu Pharmaceuticals launches Sandu Kumarvin

Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.

PIB: Budget allocation and utilization of funds under National Ayush Mission

The total budget of Rs. 3119.46 crores has been allocated/ released as a central share to States/UTs since the inception of the scheme and they have reported an expenditure of Rs. 2290.20 crores.

PIB: Quality control of Ayush drugs

PIB: Development of Ayush entrepreneurship

Ministry of Ayush signed a MoU with Ministry of Micro, Small & Medium Enterprises (MSME) for the promotion of Ayush enterprises.

PIB: Pharmaceutical industry in Maharashtra

The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.